In addition, Formononetin, as an inhibitor of EGFR, inhibited EGFR-Akt signaling by binding to the ATP-binding pocket region of both wild-type and mutant EGFR, promoting the ubiquitination and degradation of Mcl-1, thereby inhibiting the proliferation of non-small cell lung cancer [105]. Here, EGFR is linked to non-small cell lung carcinoma.